In addition, the Genomics of Drug Sensitivity in Cancer (GDSC) database shows that cancer cells with EWS-FLI1 mutations are preferentially sensitive to elesclomol as compare with the wide-type counterparts (http://www.cancerrxgene.org/translation/Drug/1031#t_scatter_1031), which is consistent with our in vitro drug screens. Here, EWSR1 is linked to cancer.